Avacta to present data at EORTC-NCI-AACR
Avacta Group PLC announced the presentation of data on its first dual-payload peptide drug conjugate (PDC) at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston on October 25. The data highlights the development of a platform that delivers two complementary drugs via a single pre|CISION medicine, representing the first dual payload PDC in the field. The in vitro data demonstrates proof of mechanism for this innovation, which extends the pre|CISION technology to allow for the selective and controlled release of two cancer-targeting payloads directly in the tumor via fibroblast activation protein (FAP) cleavage, expressed in more than 90% of solid tumors.
Select text to share a quote on X · sign in to keep highlights & notes in your AVCT notes
| Avacta to Present First Dual Payload pre | CISION® Medicines Data at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets Symposium |
Groundbreaking oncology development with the first dual payload peptide drug conjugate platform, establishing Avacta as a leader in combination therapy innovation
| LONDON and PHILADELPHIA - October 13, 2025 - Avacta Therapeutics (AIM: AVCT, 'Avacta', 'the Company'), a clinical stage biopharmaceutical company developing pre | CISION®, a unique oncology delivery platform, today announces that the Company will present data on its first dual-payload peptide drug conjugate (PDC) at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston on October 25. |
| The data highlights the Company's proprietary development enabling two complementary drugs to be delivered via a single pre | CISION® medicine, representing the first dual payload PDC in the field. Data presented will be in vitro proof of mechanism for this platform innovation. |
| Drug combinations are commonly used in cancer therapy to improve outcomes and mitigate against resistance. This novel approach extends the pre | CISION® technology to allow for the selective and controlled release of two cancer-targeting payloads directly in the tumor, from a single molecule via fibroblast activation protein (FAP) cleavage. |
| Previously, development of the pre | CISION® platform focused on optimizing the delivery of single payloads to the tumor microenvironment leveraging the cleavage event by FAP, expressed in more than 90% of solid tumors. The new dual payload innovation expands the platform's versatility, opening potential for more complex and effective oncology treatments. |
Christina Coughlin, M.D., Ph.D., Chief Executive Officer of Avacta, said:
| "The development of the first dual payload peptide drug conjugate platform marks a major leap forward in oncology therapy. This significantly extends the potential of our innovative pre | CISION® platform by implementing combination cancer therapy in a single medicine. |
| "This new IP builds on the success of our FAP-EXd (AVA6103) program, where we invented a sustained release delivery mechanism with the platform. Our novel implementation of the platform extends this observation to now release two drugs from one pre | CISION® molecule. The key factor here is our ability to target the tumor with a cytotoxic drug and attack the known resistance mechanism all in one cancer medicine. By building on the prior knowledge, we have now extended the reach to highly-resistant cancers by targeting key resistance mechanisms. |
| This drug combination approach demonstrates the value we are building in our proprietary pre | CISION® technology by further underlining its flexibility and unique potential to expand into novel oncology therapeutic approaches. |
We look forward to presenting the full data at the 2025 EORTC-NCI-AACR Symposium later this month."
Event details are below and are available online on the 2025 EORTC-NCI-AACR Symposium website.
| Title: Discovery and characterization of novel pre | CISION® technology compounds delivering complementary dual payloads to the tumor microenvironment following FAP cleavage |
Authors: Tom Clough, Alexa Kennedy, Ellen Watts, Iva Zlatareva, Folake Orafidiya, Hanna Buist, Jannah Jeon, Sophie Brown, Doug Sammon, Victoria Juskaite, David Jones, Dave Liebowitz, Michelle Morrow, Francis Wilson
Speaker: Francis Wilson
Session: Poster Session C
Date and Time: Saturday, October 25, 12:30-4pm
| About pre | CISION® |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.